Company profile: Terremoto Bio
1.1 - Company Overview
Company description
- Provider of a lysine-targeted covalency drug discovery and development platform to create optimized small-molecule medicines against a wide range of protein targets, including those previously considered undruggable. Offerings include structure-based drug design, screening platform development, cryo-EM, X-ray crystallography, and a computational discovery engine to accelerate new medicine creation.
Products and services
- Drug Discovery and Development Engine: An integrated, modular engine that architects structure-based drug design, builds screening platform development, and deploys cryo-electron microscopy, X-ray crystallography, and a computational discovery engine to expedite new medicines
- Lysine-Targeted Covalency Platform: A custom-engineered platform that produces small-molecule medicines using lysine-based covalent chemistry to engage a wide range of protein targets, including previously undruggable proteins
- Optimized Medicines: Covalent, small-molecule products engineered via lysine-based chemistry to therapeutically engage diverse protein targets, extending reach to previously undruggable proteins
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Terremoto Bio
Grey Wolf Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antigen modulation therapies that control T cell activation by modulating antigen presentation. Offers ERAP1 and ERAP2 inhibition to generate and upregulate cancer antigens, MHCI-directed therapies to identify novel antigens, and GRWD5769, a selective ERAP1 inhibitor in EMITT-1, an adaptive Phase 1/2 clinical trial assessing monotherapy and combinations with anticancer treatments in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grey Wolf Therapeutics company profile →
Aadi Bioscience
HQ: United States
Website
- Description: Provider of a potential mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aadi Bioscience company profile →
Notable
HQ: United States
Website
- Description: Provider of personalized drug combination testing for cancer patients and a Predictive Medicine Platform (PMP) that predicts patient response to specific therapies to identify responsive patients before treatment. Develops therapeutics, including Presponse Therapeutics and the PLK-1 inhibitor volasertib, with development guided by predictive patient response data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Notable company profile →
Apollomics
HQ: United States
Website
- Description: Provider of oncology biopharmaceuticals discovering and developing mono- and combination therapies to harness the immune system. Pipeline: APL-502 (PD-L1 mAb) and APL-501 (PD-1 mAb) outside mainland China; EO1001/APL-122 (small molecule) for development outside mainland China, Hong Kong and Taiwan; uproleselan/APL-106 and GMI-1687/APL-108 (E-selectin antagonists) in mainland China, Hong Kong, Macau and Taiwan; TYG100/APL-810 in Greater China and South Africa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apollomics company profile →
Argos Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Conducts clinical trial programs in cancer and HIV. Product candidates include AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, and CD83.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Terremoto Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Terremoto Bio
2.2 - Growth funds investing in similar companies to Terremoto Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Terremoto Bio
4.2 - Public trading comparable groups for Terremoto Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →